Form 4: Nuvalent CLO Sells Shares After Option Exercise

Nuvalent's Chief Legal Officer, Deborah Ann Miller, exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

Summary

• Deborah Ann Miller, Chief Legal Officer of Nuvalent, Inc. (NUVL), executed transactions involving Class A Common Stock on October 20, 2025.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on November 18, 2024.
• Miller exercised options to acquire 5,000 shares of Class A Common Stock at an exercise price of $6.89 per share.
• Immediately following the exercise, Miller sold 5,000 shares of Class A Common Stock at a weighted average price of $94.91 per share, with prices ranging from $94.80 to $95.00.
• After these transactions, Miller beneficially owns 49,086 shares of Class A Common Stock directly and 140,608 stock options.
• The stock options underlying the exercised shares were fully vested.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it involves insider selling, the execution under a pre-established 10b5-1 plan mitigates concerns about opportunistic selling and indicates a planned, transparent transaction. The profitability for the insider is also a positive sign for the value of the company's equity.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and transparent approach to insider stock sales rather than opportunistic selling.
• The significant difference between the option exercise price ($6.89) and the sale price ($94.91) demonstrates substantial profitability for the Chief Legal Officer from her equity compensation.

Negatives

• The sale of shares by a Chief Legal Officer, even under a 10b5-1 plan, could be perceived by some investors as a lack of conviction, though this is mitigated by the pre-planned nature and the fact that a substantial number of options and shares are still held.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2024.
• The price reported for the sale is a weighted average price, with shares sold in multiple transactions ranging from $94.80 to $95.00.
• The shares underlying the exercised option are fully vested.

Industry Context

This filing reports a routine insider transaction and does not provide information directly related to broader industry trends or competitive positioning.

Corporate Governance

Stakeholder Impact

• Shareholders: The transaction is a routine insider sale under a pre-planned schedule, which typically has minimal direct impact on other shareholders. The transparency of the 10b5-1 plan can reassure investors regarding the nature of the sale.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

The filing details a routine insider transaction (exercise and sale) executed under a pre-established 10b5-1 trading plan. This type of transaction is generally not indicative of a change in fundamental company outlook or a strong signal for immediate investment action, thus a 'hold' recommendation is appropriate. Investors should consider broader company fundamentals and market conditions rather than this single, pre-planned insider transaction.

Keywords

Nuvalent, NUVL, insider trading, Form 4, stock options, 10b5-1 plan, Deborah Ann Miller, Chief Legal Officer